SynAct Pharma
8.49 SEK +3.16%1 investor is following this company
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SYNACT
Daily low / high price
8.195 / 8.55
SEK
Market cap
350.61M SEK
Turnover
798.24K SEK
Volume
96K
Latest videos
Financial calendar
Interim report
20.08.2024
Interim report
30.10.2024
Annual report
18.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sanos Group NBCD | 9.6 % | 9.6 % |
Thomas Jonassen | 6.2 % | 6.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
Bulletin from the annual general meeting 2024 in SynAct Pharma AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools